組織概要

GOTIC-015 GOTIC-VTE試験(介入研究)
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial Yoshifumi Takahashi, Hiroyuki Fujiwara, Kouji Yamamoto, Masashi Takano, Morikazu Miyamoto, Kosei Hasegawa, Maiko Miwa, Toyomi Satoh, Hiroya Itagaki, Takashi Hirakawa, Mayuyo Mori-Uchino, Tomonori Nagai, Yoshinobu Hamada, Soichi Yamashita, Hiroko Yano, Tomoyasu Kato, Keiichi Fujiwara, Mitsuaki Suzuki, and on behalf of the GOTIC-VTE Trial Investigators Journal of Gynecologic Oncology 2024 Jul;35(4):e37 DOI:10.3802/jgo.2024.35.e37
GOTIC-019 後方視的研究
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study Shoji Nagao, Jun Tamura, Takashi Shibutani, Miko Miwa, Tomoyasu Kato, Ayumi Shikama, Yuji Takei, Natsuko Kamiya, Naoki Inoue, Kazuto Nakamura, Aya Inoue, Koji Yamamoto, Keiichi Fujiwara, Mitsuaki Suzuki International Journal of Clinical Oncolgy DOI:10.1007/s10147-023-02329-7
GOTIC-001 JGOG 3019 試験
Intraperitoneal Carboplatin for Ovarian Cancer -A Phase 2/3 Trial Shoji Nagao, Keiichi Fujiwara, Kouji Yamamoto, Hiroshi Tanabe, Aikou Okamoto, Kazuhiro Takehara, Motoaki Saito, Hiroyuki Fujiwara, David S.P. Tan, Satoshi Yamaguchi, Sosuke Adachi, Akira Kikuchi, Takeshi Hirasawa, Takeshi Yokoi, Tomonori Nagai, Toyomi Sato, Shoji Kamiura, Akira Fujishita, Wong Wai Loong, Karen Chan, Peter Syks, Alexsander Olawaye, Sang-Young Ryu, Hiroyuki Shigeta, Eiji Kondo, Yoshihito Yokoyama, Takashi Matsumoto, Kosei Hasegawa and Takayuki Enomoto The New England Journal of Medeicine EvidenceNEJM Evid 2023;2(5) DOI:10.1056/EVIDoa2200225
GOTIC-031 Vivli試験
Feasibility of New Method for the Prediction of Clinical Trial Results Using Compressive Sensing of Artificial Intelligence GOTIC Study. Yasunari Miyagi, Keiichi Fujiwara, Hisanaga Nomura, Koji Yamamoto, Robert L Coleman British Journal of Healthcare and Medical Research Vol.10, No.1 Publication Date: February 25, 2023 Doi:10.14738/jbemi.101.14061.
GCIG Symptom Benefit Consensus Review
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. H. Woopen, J. Sehouli, A. Davis, Y.C. Lee, P.A. Cohen, A. Ferrero, N. Gleeson, A.Jhingran, Y. Kajimoto, J. Mayadev, M.P. Barretina-Ginesta, S. Sunder, N. Suzuki, E. van Dorst, F. Joly Cancer Treatment Reviews 107 (2022) 102396 Doi.org/10.1016/j.ctrv.2022.102396
GOTIC-016 JAVELIN Ovarian 200 試験
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, Amit M Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary E Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee, Alexandra Leary, Anna V Tinker, Kyung Hae Jung, Radoslaw Madry, Sang-Yoon Park, Charles K Anderson, Fabian Zohren, Ross A Stewart, Caimiao Wei, Samuel S Dychter, Bradley J Monk Lancet Oncol. doi:10.1016/S1470-2045(21)00216-3 Published online June 15, 2021
GOTIC-013
ALIENOR 試験
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors(The ALIENOR/ENGOT-ov7 Randomized Clinical Trial) Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, Ce´cile Dalban, Ignace Vergote, Keiichi Fujiwara, Laurence Gladieff, Hans-Joachim Lu¨ck, Anne Floquet, Annick Chevalier-Place, Andreas Schnelzer, Sandro Pignata, Fre´de´ric Selle, Jalid Sehouli, Fabien Brocard, Giorgia Mangili Patricia Pautier, Ugo De Giorgi, Magali Provansal, Pierre-Etienne Heudel JAMA Oncol. doi:10.1001/jamaoncol.2020.4574 Published online October 8.2020
GOTIC-014
PAOLA-1 試験
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial Keiichi Fujiwara, Hiroyuki Fujiwara, Hiroyuki Yoshida, Toyomi Satoh, Kan Yonemori, Shoji Nagao, Takashi Matsumoto, Hiroaki Kobayashi, Hughes Bourgeois, Philipp Harter, Anna Maria Mosconi, Isabel Palacio Vazquez, Alexander Reinthaller, Tomoko Fujita, Philip Rowe, Eric Pujada-Lauraine, Isabelle Ray-Coquard J Gynecol Oncol. 2021 Sep;32(5):e82 doi:10.3802/jgo.2021.32.e82 Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. Ray-Coquard I, Pautier P, Pignata S, Pe´rol D, Gonza´lez-Marti´n A, Berger R, Fujiwara K, Vergote I, Colombo N, Ma¨enpa¨a¨ J, Selle F, Sehouli J, Lorusso D, Guerra Ali´a E M, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme´ F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P. N Engl J Med 2019 Dec; 381:2416-2428. Doi:10.1056/NEJMoa1911361
GCIG Rare Tumour Consensus ReviewUterine serous carcinoma. Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Po´ka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Gynecol Oncol. 2021 Apr 29:S0090-8258(21)00349-8. doi:10.1016/j.ygyno.2021.04.029. Epub ahead of print. PMID: 33934848.
GCIG Symptom Benefit Brainstorming MeetingIncorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, De Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M, on behalf of the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee Gynecol Oncol. 2021(161)502-507 doi:10.1016/j.ygyno.2021.02.018
GOTIC-011
後方視的研究
Treatment-related leukemia after taxane and platinum therapy in gynecological cancer patients (Gynecologic Oncology Trial and Investigation Consortium 011). Sakurai M, Satoh T, Nakamura Y, Takei Y, Takahashi S, Fujiwara H, Nakamura K, Kanuma T, Fujiwara K and Suzuki M J. Obstet. Gynaecol. Res. 2021 doi:10.1111/jog.14760
GOTIC-014 PAOLA-1 /
GINECO-OV125b 試験
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. Ray-Coquard I, Pautier P, Pignata S, Pe´rol D, Gonza´lez-Marti´n A, Berger R, Fujiwara K, Vergote I, Colombo N, Ma¨enpa¨a¨ J, Selle F, Sehouli J, Lorusso D, Guerra Ali´a E M, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme´ F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P. N Engl J Med 2019 Dec; 381:2416-2428. Doi:10.1056/NEJMoa1911361
GOTIC-003
iPLAS 試験
A phaseUrandomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer. (GOTIC003/intergroup study)
Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, Yoshino K, Kawano Y, Hirashima Y, Nagase S, Nishio S, Nishikawa T, Ito K, Shoji T, Kimura E, Takano T, Sugiyama T, Kigawa J, Fujiwara K, Suzuki M. Int. J. Clin Oncol. 2019 Oct; 24(10):1284-1291. doi: 10.1007/s10147-019-01471-5
GOTIC-012 / ANZGOG 0701
Symptom Benefit試験
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.
Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.
2017.10.019. Epub 2017 Oct 26.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group.
Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047 Epub 2017 Jun 8.
GOTIC-006
後方視的研究
Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors. (GOTIC Study) Nakamura K, Kitahara Y, Satoh T, Takei Y, Takano M, Nagao S, Sekiguchi I, Suzuki M. World J Surg Oncol. 2016;14:173. doi: 10.1186/s12957-016-0931-4
GOTIC-007
後方視的研究
Evaluation of endometrial cytology: cytohistological correlations in 1,441 cancer patients. Fujiwara H, Takahashi Y, Takano M, Miyamoto M, Nakamura K, Kaneta Y, Hanaoka T, Ohwada M, Sakamoto T, Hirakawa T, Fujiwara K, Suzuki M. Oncology. 2015;88(2):86-94. doi: 10.1159/000368162
GCIG Rare Tumour Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-S95. doi: 10.1097/IGC.0000000000000297
GCIG Rare Tumour Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Fujiwara H, Yokota H, Monk B. Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-S101. doi: 10.1097/IGC.0000000000000263
GCIG Rare Tumour Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-S108. doi: 10.1097/IGC.0000000000000262
GOITC-005
後方視的研究
Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, Nakamura K, Kurosaki A, Satoh T, Fujiwara H, Nagao S, Furuya K, Yokota H, Ito K, Minegishi T, Yoshikawa H, Fujiwara K, Suzuki M. Br J Cancer. 2013 Oct 1;109(7):1760-1765. doi: 10.1038/bjc.2013.521
SGSG-012/
GOITC-004
後方視的研究
Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T, Tanioka M, Fujiwara K, Suzuki M, Kigawa J. Gynecol Oncol. 2013 Dec;131(3):567-573. doi: 10.1016/j.ygyno.2013.09.021

↑ページトップに戻る↑